Nippon Shinyaku Co., Ltd. (4516.T) JPX

3,975.00

-80(-1.97%)

Updated at June 03 01:30PM

Currency In JPY

Nippon Shinyaku Co., Ltd.

Address

14, Nishinosho-Monguchi-cho

Kyoto, 601-8550

Japan

Phone

81 7 5321 1111

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

2213

First IPO Date

January 01, 2001

Key Executives

NameTitlePayYear Born
Katsumi NodaCorporate Officer & Department Manager of Tokyo Business Office0N/A
Keiichi KuwanoGM of Research & Development and Director01967
Mitsuharu KoizumiHead of Dir., Pers., Gen. Affairs, Risk Man.,Comp. & Dig. Trans. Dept. (Pers. & DX) and Corp. Off.0N/A
Hideyuki FujiiAccounting & Finance Department Manager0N/A
Hitoshi IshizawaGM of Functional Food Division & Director01961
Toru YamaguchiCorporate Officer & Department Manager of Odawara Central Factory0N/A
Yoko NakanishiCorporate Officer & Department Manager of Human Resources Dept.0N/A
Toru NakaiPresident & Director01971
Kazuyuki YamateCorporate Officer & Head of Digital Transformation Div.0N/A
Manabu BeppuCorporate Officer and Head of R & D Planning and Administration Div.0N/A
Takashi TakayaGM of Personnel, General Affairs, Risk Mgmt, Compliance & Digital Trans and Director01960
Hitomi KimuraDirector of Resource Procurement, Production & Assurance & Director01961
Yoshizumi TanakaHead of Regulatory Affairs Supervision & Assurance Division and Corporate Officer0N/A
Kazuyuki IwataDirector of Sales and Marketing & Director01966
Masaya TodaHead of Licensing & Alliance Division and Corporate Officer0N/A
Hayato WadaCorporate Officer & Department Manager of Kansai Business Office0N/A
Takanori EdamitsuHead of Business Management & Sustainability and Director01963

Description

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.